

## SUPPLEMENTARY MATERIAL

**Supplementary Table 1.** Clinical and Pathological Characteristics of AML Patient Samples Tested in the Current Study.

| Sample ID | Age | Sex | Sample | WHO Diagnosis                    | Fab* | WCC   | BM blasts % | Karyotype   | NPM1     | FLT3-ITD |
|-----------|-----|-----|--------|----------------------------------|------|-------|-------------|---|----------|----------|
| 1         | 77  | F   | PB     | AML with MDS changes             | M2   | 128   | 55          | Normal  | NT       | NT       |
| 2         | 76  | F   | BM     | AML NOS                          | M4   | 14.1  | 70          | Normal  | NT       | NT       |
| 3         | 74  | M   | PB     | AML NOS                          | M2   | 15.5  | 43          | +8  | NT       | NT       |
| 4         | 70  | M   | BM     | Therapy related myeloid neoplasm | M4   | 16.4  | 82          | Normal  | Detected | Detected |
| 5         | 79  | M   | PB     | Therapy related myeloid neoplasm | M4   | 150   | 67          | 46, XY, add(12)(q24.3)                                      | NT       | NT       |
| 6         | 89  | M   | PB     | AML with MDS changes             | M2   | 30.1  | 16          | Normal  | NT       | NT       |
| 7         | 75  | M   | PB     | RAEB-2                           | N/A  | 3.5   | 15          | +8  | NT       | NT       |
| 8         | 59  | M   | PB     | AML NOS                          | M5   | 146   | 95          | Normal  | NT       | NT       |
| 9         | 51  | M   | PB     | AML NOS                          | M0   | 2.5   | 73          | No metaphases   | Negative | Negative |
| 10        | 59  | M   | PB     | AML with MDS changes             | M4   | 54.3  | 56          | Normal  | Negative | Detected |
| 11        | 81  | M   | PB     | CMML-2                           | N/A  | 5.7   | 10          | Normal  | NT       | NT       |
| 12        | 86  | F   | PB     | AML NOS                          | M1   | 23.2  | NT          | unknown   | NT       | NT       |
| 13        | 95  | F   | PB     | AML with MDS changes             | M5   | 62.7  |             | unknown   | NT       | NT       |
| 14        | 82  | M   | PB     | AML with MDS changes             | M5   | 3.8   | 53          | +19   | NT       | NT       |
| 15        | 61  | F   | BM     | AML NOS                          | M6   | 0.7   | 26%         | complex   | NT       | NT       |
| 16        | 16  | M   | BM     | AML + inversion 16               | M4Eo | 111.3 | 45          | Inversion 16  | NT       | NT       |
| 17        | 41  | F   | BM     | AML NOS                          | M5   | 5.2   | 78          | complex   | NT       | Negative |
| 18        | 75  | M   | PB     | AML with MDS changes             | M2   | 6.5   | 60          | Normal  | NT       | NT       |
| 19        | 73  | F   | PB     | AML NOS                          | M0   | 8     | 85          | Normal  | Detected | Negative |
| 20        | 72  | F   | PB     | AML with MDS changes             | M5   | 30.1  | 80          | Complex;del(12)(p12),del(13)(q21),add(17)(p11.2)[1]46,XX[1] | NT       | NT       |
| 21        | 59  | M   | BM     | AML NOS                          | M0   | 14.1  | 60          | Normal  | Negative | Negative |
| 22        | 23  | M   | BM     | AML + inversion 16               | M4Eo | 160   | 60          | 46,XY,inv(16)(p13;q22)                                      | Negative | Negative |
| 23        | 87  | M   | PB     | Therapy related myeloid neoplasm | M2   | 2.2   | 62          | 47,XY,t(8;16)(p11;p13), +8                                  | NT       | NT       |
| 24        | 24  | M   | PB     | AML NOS                          | M5   | 64    | 90          | t(11;17), +8  | Negative | Negative |
| 25        | 44  | F   | PB     | AML + inversion 16               | M4Eo | 34.9  | 50          | Inversion 16  | Negative | Negative |
| 26        | 79  | M   | BM     | AML NOS                          | M2   | 54.6  | 60          | +6  | Negative | Negative |
| 27        | 55  | M   | BM+PB  | Blastic Neoplasm pDC             | N/A  | 4.3   | 85          | Normal  | Negative | Negative |
| 28        | 61  | M   | BM     | AML NOS                          | M2   | 7     | 25          | No metaphases   | NT       | NT       |
| 29        | 44  | UD  | BM     | AML NOS                          | M1   | UD    | UD          | t(9;11)   | NT       | NT       |
| 30        | 51  | UD  | BM     | AML + inversion 16               | M4Eo | UD    | UD          | inv 16  | NT       | NT       |
| 31        | 86  | UD  | BM     | AML NOS                          | M4   | UD    | UD          | +8  | NT       | NT       |
| 32        | 19  | UD  | BM     | AML NOS                          | M2   | UD    | UD          | monosomy 7  | NT       | NT       |
| 33        | 61  | UD  | BM     | AML NOS                          | M4   | UD    | UD          | Normal  | NT       | NT       |
| 34        | 34  | M   | PB     | AML with Inv 16                  | M4eo | UD    | UD          | inv 16  | NT       | Negative |

\*M4/M5 are classed as monocytic AML, and all other subtypes as Non-monocytic AML.